Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine/cisplatin vs placebo plus gemcitabine/cisplatin in recurrent or metastatic nasopharyngeal carcinoma
CTR20182534Phase 3Completed
- Sponsor
- BeiGene
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by BeiGene. Started Mar 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20182534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182534.